Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 65th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 9-12, 2023, in San Diego, CA, and virtually, and is the world's biggest hematology event of the year. This event brought leading hemonc experts from all over the world together to discuss cutting-edge research in hematological malignancies.
View all videos

ASH 2023

The 65th ASH Annual Meeting and Exposition
09–12 December 2023 | San Diego, CA / Online

ASH 2023

The 65th ASH Annual Meeting and Exposition
09–12 December 2023 | San Diego, CA / Online
The 65th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 9-12, 2023, in San Diego, CA, and virtually, and is the world's biggest hematology event of the year. This event brought leading hemonc experts from all over the world together to discuss cutting-edge research in hematological malignancies.
View all videos

Latest videos

View all videos
1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
4:26
The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma
Benjamin Derman • 1 Dec 2023
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023

Joint discussions

View all
11:42
Thalassemia highlights at ASH 2023: novel therapies, trial updates & the value of precision medicine
Kevin Kuo et al. • 11 Dec 2023
10:30
SCD highlights at ASH 2023: disease pathogenesis, ongoing clinical trials & novel gene therapies
Josu de la Fuente et al. • 12 Dec 2023

AML

View all
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
1:19
ASTX727 + a molecularly-targeted agent as personalized maintenance therapy in patients with AML
Tapan Kadia • 14 Dec 2023

Lymphoma

View all
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
2:06
Odronextamab in CAR-T relapsed diffuse large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023

CLL

View all
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
1:19
The prognostic value of MRD in CLL
Joanna Rhodes • 11 Dec 2023

Multiple myeloma

View all
1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
4:26
The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma
Benjamin Derman • 1 Dec 2023

MPNs

View all
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023

Non-Malignant

View all
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
0:59
HdxSim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in SCD
Alexandra Power-Hays • 11 Dec 2023

Amyloidosis

View all
1:55
Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis
Vaishali Sanchorawala • 11 Dec 2023
1:55
Quantifying biomarkers on lambda amyloidogenic light chains to diagnose AL amyloidosis
Vaishali Sanchorawala • 11 Dec 2023
The content of VJHemOnc is intended for healthcare professionals